# US 2011/0217330 A1 · Novel method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0217330 A1
- Document ID: US20110217330A1
- Status: Published application
- Kind: A1
- Application number: 13/127,825
- Filed: 2009-11-03
- Published: 2011-09-08
- Earliest claimed: 2008-11-05
- Inventors: Bruno Rene Andre; Benoit Paul Suzanne Champluvier; Bénédicte Van Der Heyden
- Web page: https://patentgrep.com/patent/US20110217330A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16251: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuclease and ii) a DNA alkylating agent.

## Claims

### Claim at position 1

-44. (canceled)

### Claim 45

A method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two host cell nucleic acids degradation steps with a compound selected from i) an endonuclease and ii) a DNA alkylating agent.

### Claim 46

A method for producing a virus or a viral antigen thereof in cell culture comprising the steps of:
a. providing a population of host cells cultured in a cell culture medium,
b. inoculating the population of host cells with a virus,
c. culturing the population of host cells so as to allow the virus to replicate,
d. collecting the produced virus thereby providing a viral harvest, and
e. isolating the virus,
the method further comprising at least two host cell nucleic acids degradation steps with a compound selected from i) an endonuclease and ii) a DNA alkylating agent.

### Claim 47 (depends on 46)

The method according to claim 46, wherein one of the host cell nucleic acids degradation steps is implemented before step (d).

### Claim 48 (depends on 47)

The method according to claim 47, wherein the nucleic acids degradation step implemented before step (d) is performed with an endonuclease.

### Claim 49 (depends on 46)

The method according to claim 46, wherein one of the host cell nucleic acids degradation steps is performed by adding an endonuclease to the viral harvest obtained after step (d).

### Claim 50 (depends on 46)

The method according to claim 46, wherein one of the host cell nucleic acids degradation steps is implemented during the virus isolating of step (e).

### Claim 51 (depends on 46)

The method according to claim 46, wherein the virus isolating step comprises at least one step selected from viral harvest clarification, ultrafiltration, ultracentrifugation and chromatography, or any combination thereof.

### Claim 52 (depends on 51)

The method according to claim 51, wherein the virus isolating step comprises at least one ultrafiltration step, and wherein the ultrafiltration step produces a retentate.

### Claim 53 (depends on 52)

The method according to claim 52, wherein an endonuclease is added to the retentate.

### Claim 54 (depends on 51)

The method according to claim 51, wherein the virus isolating step comprises at least one step of sucrose gradient ultracentrifugation.

### Claim 55 (depends on 46)

The method according to claim 46, wherein one of the host cell nucleic acids degradation steps is performed with a DNA alkylating agent.

### Claim 56 (depends on 52)

The method according to claim 52, wherein a DNA alkylating agent is added to the retentate obtained after ultrafiltration.

### Claim 57 (depends on 48)

The method according to claim 48, further comprising a second host cell nucleic acids degradation step with a DNA alkylating agent, wherein the second host cell nucleic acids degradation step is implemented during the virus isolating step of (e).

### Claim 58 (depends on 46)

The method according to claim 46, further comprising a virus splitting step.

### Claim 59 (depends on 58)

The method according to claim 58, wherein the virus splitting step comprises adding octylphenoxypolyethoxyethanol (TRITON™ X-100),

### Claim 60 (depends on 59)

The method of according to claim 59, further comprising adding deoxycholate or sodium lauryl sulfate.

### Claim 61 (depends on 46)

The method according to claim 46, wherein the alkylating agent is beta-propiolactone.

### Claim 62 (depends on 46)

The method according to claim 46, wherein the host cells are selected from the group consisting of mammalian cells and avian cells.

### Claim 63 (depends on 62)

The method according to claim 62 wherein the host cells are selected from the group consisting of MDCK cells and embryonic duck stem cells.

### Claim 64 (depends on 46)

The method according to claim 46, wherein the virus is influenza virus.

### Claim 65

An immunogenic composition comprising a cell culture-produced virus, or a viral antigen thereof, admixed with a suitable pharmaceutical carrier, wherein the residual host cell content of DNA fragments whose length is 300 base pairs is less than 1 ng as measured by quantitative PCR.

### Claim 66 (depends on 65)

The composition according to claim 65, having a total residual host cell DNA content of less than 100 μg, as measured by a THRESHOLD™ assay, and wherein the content of DNA fragments whose length is 300 base pairs is less than 10 μg, as measured by quantitative PCR.

### Claim 67 (depends on 65)

The composition according to claim 65, wherein the residual host cell content of DNA fragments whose length is 60 base pairs is less than 1 ng as measured by quantitative PCR

### Claim 68

An immunogenic composition comprising a cell culture-produced virus, or a viral antigen thereof, admixed with a suitable pharmaceutical carrier, wherein the residual host cell content of DNA fragments whose length is 60 base pairs is less than 1 ng as measured by quantitative PCR.

### Claim 69 (depends on 68)

The composition according to claim 68, having a total residual host cell DNA content of less than 100 μg, as measured by a THRESHOLD™ assay, and wherein the content of DNA fragments whose length is 60 base pairs is less than 10 μg, as measured by quantitative PCR.

### Claim 70 (depends on 65, 68)

The composition according to claim 65 or 68, further comprising an adjuvant.

### Claim 71 (depends on 65, 68)

A method of treating or preventing a viral disease in a human or animal comprising administering the composition of claim 65 or 68 to the human or animal.
